4D Molecular Therapeutics, Inc. - Common Stock (FDMT)

Competitors to 4D Molecular Therapeutics, Inc. - Common Stock (FDMT)

Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is involved in creating gene therapies that focus primarily on ocular and neurological diseases, utilizing AAV vector technology similar to that of 4D Molecular Therapeutics. The direct competition lies in their capabilities in gene therapy for rare diseases where patient populations are limited but have significant unmet needs. AGTC has several programs in clinical development, giving them a current advantage in market presence.

Audentes Therapeutics, Inc.

Audentes Therapeutics focuses on developing gene therapies for rare diseases, utilizing AAV (adeno-associated virus) technology, similar to 4D Molecular Therapeutics. The companies compete in the gene delivery space, targeting muscular dystrophies and other rare genetic conditions. Audentes has established partnerships and a broader pipeline that may offer them a competitive edge in terms of market reach and clinical progress.

Regenxbio Inc. 

Regenxbio is active in the development of gene therapies using its proprietary AAV gene delivery platform for a variety of diseases including neurological and ocular disorders. The company competes directly with 4D Molecular Therapeutics by applying similar technology but has a more established pipeline in the clinic, which potentially gives it an edge in gaining market traction and partnerships.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics focuses on genomic therapies and gene editing technologies, which sets them apart from 4D Molecular Therapeutics’ more traditional gene delivery approach. They are engaged in a broader array of gene-modulating therapies, including ZFNs (zinc finger nucleases), providing them a unique position in genetic medicine. However, the complexity of gene editing may present regulatory hurdles that 4D could avoid, depending on how each company progresses through development.

Zymeworks Inc. 

Zymeworks develops therapeutic proteins and antibody-drug conjugates for oncology and other therapeutic areas and has a proprietary platform for protein engineering, which can provide flexibility and efficiency in drug development. While not directly a gene therapy company like 4D, they compete in the biotherapeutics market with a strong focus on next-generation therapies, leveraging their platform for a wide range of applications.